Department of Surgery, Keio University School of Medicine, Tokyo, Japan.
Department of Preventive Medicine and Public Health, Keio University School of Medicine, Tokyo, Japan.
Ann Surg Oncol. 2021 Oct;28(11):6355-6363. doi: 10.1245/s10434-020-09545-9. Epub 2021 Mar 21.
The tumor, node, metastasis staging system of the Union for International Cancer Control (UICC) has been used worldwide for esophageal cancer, and, in Japan, the Japan Esophageal Society Japanese Classification of Esophageal Cancer (JES) has also been used; however, there is a big difference between the two classifications with regard to node staging. We hypothesized that these two node staging systems may lead to different outcome predictions in terms of tumor location.
This study enrolled 409 patients who underwent esophagectomy at Keio University Hospital, Tokyo, Japan, between January 2005 and December 2017. We included those who underwent R0 or R1 resection or esophagectomy with additional organ excision, and excluded those who underwent salvage surgery. Thereafter, we investigated how the number or spread of metastatic lymph nodes affected the prognosis.
For all 409 patients, the 5-year overall survival rate was 64.1% and the 5-year recurrence-free survival rate was 58.4%. The concordance indices were 0.756 for UICC 8th edition pathological node staging and 0.732 for JES 11th edition pathological node staging (p = 0.06). Based on tumor location, the difference in the concordance indices between these two classifications was greatest for lower thoracic esophageal tumors (p = 0.02).
For all patients, the UICC 8th edition node staging system tended to reflect survival more precisely than that of the JES 11th edition. For lower thoracic esophageal tumors in particular, the former node staging system could be more useful.
国际癌症控制联盟(UICC)的肿瘤、淋巴结、转移分期系统已在全球范围内用于食管癌,在日本,日本食管协会日本食管癌分类(JES)也在使用;然而,这两种分类在淋巴结分期方面存在很大差异。我们假设这两种淋巴结分期系统可能会导致肿瘤位置不同的预后预测结果不同。
本研究纳入了 2005 年 1 月至 2017 年 12 月期间在日本庆应义塾大学医院接受食管癌切除术的 409 例患者。我们纳入了接受 R0 或 R1 切除或伴有其他器官切除的食管癌切除术的患者,并排除了接受挽救性手术的患者。此后,我们研究了转移淋巴结的数量或扩散如何影响预后。
对于所有 409 例患者,5 年总生存率为 64.1%,5 年无复发生存率为 58.4%。UICC 第 8 版病理淋巴结分期的一致性指数为 0.756,JES 第 11 版病理淋巴结分期的一致性指数为 0.732(p=0.06)。根据肿瘤位置,这两种分类之间的一致性指数差异最大的是下胸段食管癌(p=0.02)。
对于所有患者,UICC 第 8 版淋巴结分期系统比 JES 第 11 版更能准确地反映生存率。特别是对于下胸段食管癌,前者的淋巴结分期系统可能更有用。